Cargando…

Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients

BACKGROUND: The presence of antiphospholipid antibodies (aPLs) plays a pivotal role in the pathogenesis of antiphospholipid antibody syndrome (APS). This study aimed to examine the diagnostic value of a set of non−criteria aPLs and their relevance with APS-related criteria and extra-criteria manifes...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Siting, Bai, Yina, Meng, Jingjing, Wang, Qian, Tian, Xinping, Li, Mengtao, Zeng, Xiaofeng, Zhao, Jiuliang, Hu, Chaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132625/
https://www.ncbi.nlm.nih.gov/pubmed/37122726
http://dx.doi.org/10.3389/fimmu.2023.1107510
_version_ 1785031426301755392
author Li, Siting
Bai, Yina
Meng, Jingjing
Wang, Qian
Tian, Xinping
Li, Mengtao
Zeng, Xiaofeng
Zhao, Jiuliang
Hu, Chaojun
author_facet Li, Siting
Bai, Yina
Meng, Jingjing
Wang, Qian
Tian, Xinping
Li, Mengtao
Zeng, Xiaofeng
Zhao, Jiuliang
Hu, Chaojun
author_sort Li, Siting
collection PubMed
description BACKGROUND: The presence of antiphospholipid antibodies (aPLs) plays a pivotal role in the pathogenesis of antiphospholipid antibody syndrome (APS). This study aimed to examine the diagnostic value of a set of non−criteria aPLs and their relevance with APS-related criteria and extra-criteria manifestations. METHODS: From a prospectively constructed database, consecutive APS patients consisting of 114 primary APS (PAPS group), 54 with APS secondary to SLE (SAPS group), 9 seronegative APS (SNAPS), as well as 209 patients with systemic lupus erythematosus (SLE) and 88 healthy controls were included in this study. Levels of criteria aPLs, baseline information, and APS-related criteria and extra-criteria features were extracted from the database. Serum levels of non-criteria aPLs including aPC IgG/IgM, aPI IgG/IgM, aPE IgG/IgM/IgA, aPG IgG/IgM/IgA, anti-phosphatidic acid (aPA) IgG/IgM, aSM IgG/IgM, and aPS/PT IgG/IgM were analyzed with AESKULISA® ELISA Test Kits. RESULTS: The addition of aPC IgG/M, aPI IgG/M, aPE IgG/M/A, aSM IgG/M, and aPA IgG/M to aCL or aβ2GPI IgG/M could significantly increase diagnostic sensitivity and accuracy. A significant difference between PAPS or SAPS and HC was presented in all non-criteria aPLs except for aSM IgM and aPG IgA. Eight out of nine SNAPS patients were positive for at least 1 aPL. Pregnancy morbidity was associated with aSM IgM (r = 0.22) and aSM IgG (r = 0.15). Pre-eclampsia or premature birth was associated with aSM IgG (r = 0.16), aPI IgG (r = 0.22), aPC IgG (r = 0.16), and aPG IgG (r = 0.18). Stroke was associated with aPI IgG (r = 0.2). The clinical association was also observed in DVT with aPS/PT IgG (r = 0.17). Valve lesion was positively associated with aSM IgM (Fisher test p = 0.039), APS nephropathy was associated with aPC IgG (OR 3.797), and livedo reticularis was associated with aPE IgM (OR 15.391). CONCLUSION: Additional detection of non-criteria aPLs including aPC IgG/M, aPE IgG/M/A, aPI IgG/M, aSM IgG/M, and aPA IgG/M could assist in APS diagnosis. The positivity of certain aPLs was statistically associated with both criteria and extra-criteria APS clinical manifestations.
format Online
Article
Text
id pubmed-10132625
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101326252023-04-27 Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients Li, Siting Bai, Yina Meng, Jingjing Wang, Qian Tian, Xinping Li, Mengtao Zeng, Xiaofeng Zhao, Jiuliang Hu, Chaojun Front Immunol Immunology BACKGROUND: The presence of antiphospholipid antibodies (aPLs) plays a pivotal role in the pathogenesis of antiphospholipid antibody syndrome (APS). This study aimed to examine the diagnostic value of a set of non−criteria aPLs and their relevance with APS-related criteria and extra-criteria manifestations. METHODS: From a prospectively constructed database, consecutive APS patients consisting of 114 primary APS (PAPS group), 54 with APS secondary to SLE (SAPS group), 9 seronegative APS (SNAPS), as well as 209 patients with systemic lupus erythematosus (SLE) and 88 healthy controls were included in this study. Levels of criteria aPLs, baseline information, and APS-related criteria and extra-criteria features were extracted from the database. Serum levels of non-criteria aPLs including aPC IgG/IgM, aPI IgG/IgM, aPE IgG/IgM/IgA, aPG IgG/IgM/IgA, anti-phosphatidic acid (aPA) IgG/IgM, aSM IgG/IgM, and aPS/PT IgG/IgM were analyzed with AESKULISA® ELISA Test Kits. RESULTS: The addition of aPC IgG/M, aPI IgG/M, aPE IgG/M/A, aSM IgG/M, and aPA IgG/M to aCL or aβ2GPI IgG/M could significantly increase diagnostic sensitivity and accuracy. A significant difference between PAPS or SAPS and HC was presented in all non-criteria aPLs except for aSM IgM and aPG IgA. Eight out of nine SNAPS patients were positive for at least 1 aPL. Pregnancy morbidity was associated with aSM IgM (r = 0.22) and aSM IgG (r = 0.15). Pre-eclampsia or premature birth was associated with aSM IgG (r = 0.16), aPI IgG (r = 0.22), aPC IgG (r = 0.16), and aPG IgG (r = 0.18). Stroke was associated with aPI IgG (r = 0.2). The clinical association was also observed in DVT with aPS/PT IgG (r = 0.17). Valve lesion was positively associated with aSM IgM (Fisher test p = 0.039), APS nephropathy was associated with aPC IgG (OR 3.797), and livedo reticularis was associated with aPE IgM (OR 15.391). CONCLUSION: Additional detection of non-criteria aPLs including aPC IgG/M, aPE IgG/M/A, aPI IgG/M, aSM IgG/M, and aPA IgG/M could assist in APS diagnosis. The positivity of certain aPLs was statistically associated with both criteria and extra-criteria APS clinical manifestations. Frontiers Media S.A. 2023-04-12 /pmc/articles/PMC10132625/ /pubmed/37122726 http://dx.doi.org/10.3389/fimmu.2023.1107510 Text en Copyright © 2023 Li, Bai, Meng, Wang, Tian, Li, Zeng, Zhao and Hu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Li, Siting
Bai, Yina
Meng, Jingjing
Wang, Qian
Tian, Xinping
Li, Mengtao
Zeng, Xiaofeng
Zhao, Jiuliang
Hu, Chaojun
Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients
title Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients
title_full Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients
title_fullStr Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients
title_full_unstemmed Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients
title_short Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients
title_sort prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in chinese patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132625/
https://www.ncbi.nlm.nih.gov/pubmed/37122726
http://dx.doi.org/10.3389/fimmu.2023.1107510
work_keys_str_mv AT lisiting prevalenceanddiagnosticvalueofnoncriteriaantiphospholipidantibodiesforantiphospholipidsyndromeinchinesepatients
AT baiyina prevalenceanddiagnosticvalueofnoncriteriaantiphospholipidantibodiesforantiphospholipidsyndromeinchinesepatients
AT mengjingjing prevalenceanddiagnosticvalueofnoncriteriaantiphospholipidantibodiesforantiphospholipidsyndromeinchinesepatients
AT wangqian prevalenceanddiagnosticvalueofnoncriteriaantiphospholipidantibodiesforantiphospholipidsyndromeinchinesepatients
AT tianxinping prevalenceanddiagnosticvalueofnoncriteriaantiphospholipidantibodiesforantiphospholipidsyndromeinchinesepatients
AT limengtao prevalenceanddiagnosticvalueofnoncriteriaantiphospholipidantibodiesforantiphospholipidsyndromeinchinesepatients
AT zengxiaofeng prevalenceanddiagnosticvalueofnoncriteriaantiphospholipidantibodiesforantiphospholipidsyndromeinchinesepatients
AT zhaojiuliang prevalenceanddiagnosticvalueofnoncriteriaantiphospholipidantibodiesforantiphospholipidsyndromeinchinesepatients
AT huchaojun prevalenceanddiagnosticvalueofnoncriteriaantiphospholipidantibodiesforantiphospholipidsyndromeinchinesepatients